For suspected or existing coronary artery disease. ANDA 203779, held by 3d Imaging Drug. Ammonia N-13.
As of Nov 16, 2026, ANDA 203779 (Ammonia N 13), held by 3d Imaging Drug, was first approved by FDA on Oct 19, 2015, with 1 approved supplement and 0 published complete response letters.
Ammonia N 13 Injection is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 19, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ammonia N 1330mCi-300mCi/8ML (3.75-37.5mCi/ML) · injectable;intravenous | Ammonia N-13 | Rx |
| Jun 24, 2020 | Supplement 1Manufacturing | Approved | None posted |
| Oct 19, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters